Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Molecular Partners presents MP0712 data
Tech clinical trial update

Molecular Partners presents MP0712 data

Analysis based on 8 articles · First reported May 30, 2026 · Last updated May 30, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The announcement of Molecular Partners' progress in its Phase 1/2a study for MP0712, a targeted alpha radiotherapy for small cell lung cancer, is positive for the biotechnology and pharmaceutical sectors. Positive clinical data, expected in 2026, could significantly boost the stock price of Molecular Partners and potentially other companies in the radiopharmaceutical space.

Biotechnology Pharmaceuticals
Event Summary

Molecular Partners AG announced it will hold trial-in-progress poster presentations on its lead targeted alpha radiotherapy candidate, MP0712, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. MP0712, co-developed with Orano, is a 212Pb-based Radio-DARPin Therapy targeting DLL3 for small cell lung cancer and other neuroendocrine cancers. The US multicenter Phase 1/2a study (NCT07278479) is actively recruiting patients, with dosing ongoing in the first cohort. Molecular Partners expects to share initial clinical data from this study in 2026. Earlier data, generated with MP0712 carrying a diagnostic isotope as part of a Named Patient Access Program in South Africa, showed specific uptake in tumor lesions, supporting the clinical development plans.

Key Actions
90 Molecular Partners announced presentations
80 Molecular Partners recruiting patients
70 Molecular Partners co-developed Orano
60 Molecular Partners presented data
Entities Involved
stock
Molecular Partners
Molecular Partners is the clinical-stage biotech company developing the MP0712 Radio-DARPin Therapy and is presenting its Phase 1/2a study data at ASCO and SNMMI 2026. This event highlights its progress in targeted alpha radiotherapy.
Importance 100 Sentiment 70
priv
Orano
Orano is the strategic partner co-developing MP0712 with Molecular Partners, contributing to the advancement of targeted alpha therapy.
Importance 60 Sentiment 50
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) is hosting its Annual Meeting where Molecular Partners will present trial-in-progress poster presentations on MP0712.
Importance 40 Sentiment 0
ngo
Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is hosting its Annual Meeting where Molecular Partners will present trial-in-progress poster presentations on MP0712.
Importance 40 Sentiment 0
per
Mike Sathekge
Dr. Mike Sathekge and his team at the Nuclear Medicine Research Institute (NuMeRI) presented initial patient imaging and dosimetry data on MP0712.
Importance 30 Sentiment 0
oth
Nuclear Medicine Research Institute
The Nuclear Medicine Research Institute (NuMeRI) collaborated with Molecular Partners to present initial patient data on MP0712.
Importance 30 Sentiment 0
cnt
South Africa
South Africa is where the Named Patient Access Program for MP0712 was conducted under its legal framework for compassionate care.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.